VRCA
Verrica Pharmaceuticals Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-44/100
Last price
4.21
▼ 0.10 (2.32%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
4.31
Day high
4.41
Day low
4.17
Volume
40.63K
Market cap
$72.32M
P/E (TTM)
—
52W range
3.28 – 9.82
Trailing performance
Returnvs SPY
1W
-5.61%
-7.6%
1M
-20.57%
-21.7%
3M
-36.40%
-40.9%
6M
-27.66%
-45.8%
YTD
-49.34%
-63.6%
1Y
-9.85%
-26.3%
3Y
-89.16%
-171.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VRCA open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
8.42M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 18, 26 | KIRBY JOHN J. Chief Financial Officer |
BUY | 5.00K | $24.65K | Direct |
| Aug 18, 26 | ROSENBERG NOAH L Officer |
BUY | 6.23K | $30.61K | Direct |
| Aug 17, 26 | RIEGER JAYSON Chief Executive Officer |
BUY | 25.00K | $125.75K | Direct |
| Aug 17, 26 | ZAWITZ DAVID Chief Operating Officer |
BUY | 6.00K | $29.88K | Direct |
| Dec 23, 25 | KIRBY JOHN J. Chief Financial Officer |
STOCK | 10.00K | $0 | Direct |
| Nov 25, 25 | MANNING PAUL B. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.13M | $17.51M | |
| Nov 25, 25 | KIRBY JOHN J. Chief Financial Officer |
BUY | 3.54K | $15.00K | Direct |
| Nov 25, 25 | ROSENBERG NOAH L Officer |
BUY | 2.36K | $10.00K | Direct |
| Nov 25, 25 | RIEGER JAYSON Chief Executive Officer |
BUY | 94.31K | $400.11K | Direct |
| Nov 25, 25 | ZAWITZ DAVID Chief Operating Officer |
BUY | 10.00K | $42.42K | Direct |
| Mar 17, 25 | HAYES CHRISTOPHER G Officer |
SELL | 4.32K | $2.81K | Direct |
| Nov 26, 24 | MANNING PAUL B. Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 450.00K | $0 | Direct |
| Nov 22, 24 | MANNING PAUL B. Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 22.92M | $22.80M | |
| Nov 22, 24 | STALFORT JOHN A Director |
BUY | 1.12M | $1.12M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
HAYES CHRISTOPHER G |
Officer | 176.46K | Sale |
KIRBY JOHN J. |
Chief Financial Officer | 23.96K | Purchase |
MANNING PAUL B. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RIEGER JAYSON |
Chief Executive Officer | 208.30K | Purchase |
ROSENBERG NOAH L |
Officer | 8.59K | Purchase |
STALFORT JOHN A |
Director | 1.87M | Purchase |
ZAWITZ DAVID |
Chief Operating Officer | 27.00K | Purchase |
Fundamentals
Market cap$72.32M
Enterprise value$62.93M
Revenue (TTM)$30.32M
Gross profit$11.43M
EBITDA$-25.96M
Net income$-31.18M
EPS (TTM)$-1.75
Free cash flow$-9.04M
Total cash$11.20M
Total debt$1.81M
Book value / share$0.25
Shares outstanding17.18M
Float12.41M
Short % of float2.30%
Dividend yield0.00%
Beta (5Y)1.61
Valuation & profitability ratios
Trailing P/E—
Forward P/E-2.85
PEG ratio—
Price / sales—
Price / book16.77
EV / revenue2.08
EV / EBITDA-2.42
Gross margin37.68%
Operating margin-194.46%
Profit margin-102.84%
Return on equity—
Return on assets-43.98%
Debt / equity42.03
Current ratio1.45
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $35.58M | $7.57M | $5.12M | $9.03M | +370.2% |
| Operating revenue | $35.58M | $7.57M | $5.12M | $9.03M | +370.2% |
| Cost of revenue | $3.44M | $2.74M | $746.00K | $725.00K | +25.6% |
| Gross profit | $32.14M | $4.83M | $4.38M | $8.31M | +565.9% |
| Research & development | $8.86M | $11.84M | $20.30M | $12.20M | -25.2% |
| Selling, general & admin | $35.22M | $58.82M | $47.30M | $17.41M | -40.1% |
| Total operating expense | $44.08M | $70.66M | $67.60M | $29.60M | -37.6% |
| Operating income | -$11.94M | -$65.84M | -$63.22M | -$21.30M | +81.9% |
| Net interest income | -$6.81M | -$8.00M | -$1.22M | -$1.70M | +14.8% |
| Pre-tax income | -$17.89M | -$76.58M | -$67.00M | -$24.49M | +76.6% |
| Net income | -$17.89M | -$76.58M | -$67.00M | -$24.49M | +76.6% |
| Net income to common | -$17.89M | -$76.58M | -$67.00M | -$24.49M | +76.6% |
| Basic EPS | -1.68 | -14.80 | -14.80 | -7.20 | +88.6% |
| Diluted EPS | -1.68 | -14.80 | -14.80 | -7.20 | +88.6% |
| EBIT | -$10.14M | -$67.17M | -$63.03M | -$22.32M | +84.9% |
| EBITDA | -$9.36M | -$65.90M | -$62.20M | -$21.60M | +85.8% |
| Basic shares | 10.65M | 5.18M | 4.53M | 3.42M | +105.6% |
| Diluted shares | 10.65M | 5.18M | 4.53M | 3.42M | +105.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $30.15M | $46.33M | $69.55M | $34.27M | — | -34.9% |
| Cash & short-term investments | $30.15M | $46.33M | $69.55M | $34.27M | — | -34.9% |
| Accounts receivable | $5.26M | $48.00K | $4.25M | $388.00K | — | +10,858.3% |
| Inventory | $2.24M | $2.46M | $1.02M | $0 | — | -9.2% |
| Total current assets | $42.54M | $51.18M | $77.53M | $39.12M | — | -16.9% |
| Property, plant & equipment | $1.86M | $2.58M | $3.62M | $5.33M | — | -27.8% |
| Total assets | $47.13M | $54.13M | $81.60M | $44.72M | — | -12.9% |
| Total current liabilities | $16.44M | $29.01M | $17.02M | $3.46M | — | -43.3% |
| Current debt | — | $12.94M | — | — | $41.69M | — |
| Long-term debt | — | $30.98M | $42.87M | — | — | — |
| Total debt | $1.63M | $45.94M | $45.51M | $1.53M | — | -96.4% |
| Total liabilities | $22.39M | $63.99M | $61.83M | $4.69M | — | -65.0% |
| Retained earnings | -$324.91M | -$307.03M | -$230.45M | -$163.45M | — | -5.8% |
| Shareholder equity | $24.74M | -$9.86M | $19.76M | $40.03M | — | +350.9% |
| Working capital | $26.10M | $22.17M | $60.51M | $35.66M | — | +17.8% |
| Net tangible assets | $24.74M | -$9.86M | $19.76M | $40.03M | — | +350.9% |
| Shares issued | 17.19M | 9.19M | 4.25M | 4.12M | — | +87.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$17.89M | -$76.58M | -$67.00M | -$24.49M | — | +76.6% |
| Depreciation & amortisation | $781.00K | $1.27M | $836.00K | $718.00K | — | -38.5% |
| Stock-based compensation | $3.32M | $7.16M | $14.38M | $4.99M | — | -53.7% |
| Change in working capital | -$6.25M | $2.03M | $9.86M | -$1.80M | — | -408.4% |
| Operating cash flow | -$17.63M | -$60.93M | -$38.58M | -$18.65M | — | +71.1% |
| Capital expenditure | — | -$27.00K | -$362.00K | -$302.00K | -$883.00K | — |
| Investing cash flow | $0 | -$19.00K | -$362.00K | $54.04M | — | +100.0% |
| Financing cash flow | $1.45M | $37.73M | $74.21M | -$16.87M | — | -96.2% |
| Free cash flow | -$17.63M | -$60.95M | -$38.94M | -$18.95M | — | +71.1% |
| End cash position | $30.15M | $46.33M | $69.55M | $34.27M | — | -34.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $5.86M | $5.02M | $5.09M | $14.34M | $12.70M | +16.7% |
| Operating revenue | $5.86M | $5.02M | $5.09M | $14.34M | $12.70M | +16.7% |
| Cost of revenue | $878.00K | $889.00K | $1.40M | $1.11M | $494.00K | -1.2% |
| Gross profit | $4.98M | $4.13M | $3.69M | $13.23M | $12.21M | +20.6% |
| Research & development | $6.03M | $3.86M | $2.52M | $2.21M | $1.85M | +56.3% |
| Selling, general & admin | $10.35M | $9.99M | $8.12M | $9.40M | $8.85M | +3.6% |
| Total operating expense | $16.38M | $13.85M | $10.64M | $11.61M | $10.70M | +18.3% |
| Operating income | -$11.40M | -$9.71M | -$6.95M | $1.63M | $1.51M | -17.3% |
| Net interest income | -$53.00K | $41.00K | -$1.11M | -$1.94M | -$1.90M | -229.3% |
| Pre-tax income | -$13.15M | -$9.68M | -$8.07M | -$274.00K | $204.00K | -35.9% |
| Net income | -$13.15M | -$9.68M | -$8.07M | -$274.00K | $204.00K | -35.9% |
| Net income to common | -$13.15M | -$9.68M | -$8.07M | -$274.00K | $204.00K | -35.9% |
| Basic EPS | -0.62 | -0.45 | -0.57 | -0.03 | 0.02 | -37.8% |
| Diluted EPS | -0.62 | -0.45 | -0.57 | -0.03 | 0.02 | -37.8% |
| EBIT | -$12.99M | -$9.52M | -$6.76M | $1.82M | $2.33M | -36.4% |
| EBITDA | -$12.78M | -$9.33M | -$6.57M | $2.00M | $2.53M | -37.0% |
| Basic shares | 21.31M | 21.31M | 14.11M | 9.49M | 9.49M | 0.0% |
| Diluted shares | 21.31M | 21.31M | 14.11M | 9.49M | 9.49M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.20M | $20.60M | $30.15M | $21.10M | $15.40M | — | -45.6% |
| Cash & short-term investments | $11.20M | $20.60M | $30.15M | $21.10M | $15.40M | — | -45.6% |
| Accounts receivable | $10.94M | $7.72M | $5.26M | $7.05M | $9.19M | — | +41.6% |
| Inventory | $2.71M | $1.97M | $2.24M | $2.30M | $2.52M | — | +37.4% |
| Total current assets | $32.64M | $34.13M | $42.54M | $36.27M | $36.78M | — | -4.4% |
| Property, plant & equipment | $2.03M | $1.66M | $1.86M | $1.89M | $1.95M | — | +22.3% |
| Total assets | $36.02M | $38.79M | $47.13M | $40.90M | $39.11M | — | -7.1% |
| Total current liabilities | $22.44M | $16.22M | $16.44M | $28.91M | $29.22M | — | +38.4% |
| Current debt | — | — | — | $12.46M | $12.67M | $12.82M | — |
| Long-term debt | — | — | — | $21.62M | $24.58M | $27.81M | — |
| Total debt | $1.81M | $1.44M | $1.63M | $35.74M | $38.89M | — | +25.5% |
| Total liabilities | $31.71M | $22.73M | $22.39M | $57.94M | $56.59M | — | +39.5% |
| Retained earnings | -$347.75M | -$334.60M | -$324.91M | -$316.84M | -$316.56M | — | -3.9% |
| Shareholder equity | $4.31M | $16.05M | $24.74M | -$17.04M | -$17.48M | — | -73.2% |
| Working capital | $10.20M | $17.91M | $26.10M | $7.37M | $7.56M | — | -43.1% |
| Net tangible assets | $4.31M | $16.05M | $24.74M | -$17.04M | -$17.48M | — | -73.2% |
| Shares issued | 17.18M | 17.19M | 17.19M | 9.50M | 9.27M | — | -0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$13.15M | -$9.68M | -$8.07M | -$274.00K | $204.00K | -35.9% |
| Depreciation & amortisation | $207.00K | $194.00K | $190.00K | $184.00K | $199.00K | +6.7% |
| Stock-based compensation | $1.21M | $897.00K | $686.00K | $718.00K | $888.00K | +35.2% |
| Change in working capital | -$641.00K | -$2.02M | $2.01M | $7.93M | -$11.61M | +68.3% |
| Operating cash flow | -$9.28M | -$9.16M | -$4.59M | $9.69M | -$10.04M | -1.3% |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | -$126.00K | -$120.00K | $13.64M | -$3.98M | -$4.16M | -5.0% |
| Free cash flow | -$9.28M | -$9.16M | -$4.59M | $9.69M | -$10.04M | -1.3% |
| End cash position | $11.46M | $20.86M | $30.15M | $21.10M | $15.40M | -45.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
3.00
-28.7% from spot
ATM implied vol
25.0%
Nearest strike to spot
Skew (10% OTM)
-12.5%
Calls bid over puts
Call volume
0
Contracts, this expiry
Put volume
37
Contracts, this expiry
Heaviest call OI
5.00
0 contracts
Heaviest put OI
3.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.47 | -0.48 | -2.9% |
| Mar 2026 | -0.59 | — | — |
| Dec 2025 | -0.64 | -0.51 | +20.3% |
| Sep 2025 | -0.84 | 0.13 | +115.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.52 | 4 | $6.41M | -55.3% |
| Next quarter | -0.51 | 4 | $7.52M | +47.7% |
| Current year | -1.97 | 4 | $24.82M | -30.2% |
| Next year | -1.48 | 4 | $39.22M | +58.0% |
Analyst targets & ownership
Mean target$13.83
High target$20.00
Low target$9.00
Implied upside228.58%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy0 / 6
Hold1
Sell / Strong sell0 / 0
Held by insiders49.00%
Held by institutions27.14%
Institutions holding48
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.46
-5.65% from price
SMA 20
4.59
-8.22% from price
SMA 50
4.93
-14.57% from price
SMA 100
5.43
-22.49% from price
SMA 200
6.01
-29.94% from price
EMA 12
4.49
-6.16% from price
EMA 26
4.67
-9.92% from price
EMA 50
4.93
-14.59% from price
RSI (14)
38.1
Neutral
MACD (12,26,9)
-0.19
Hist -0.01
ATR (14)
0.31
7.29% of price
Realised vol 30D
62.3%
Annualised
Bollinger upper
5.03
20, 2σ
Bollinger lower
4.15
20, 2σ
50 / 200 cross
Death
4.93 vs 6.01
Trend bias
Below 200
-29.94%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.00
More volatile than market
Correlation to SPY
0.28
Largely independent
Realised vol 30D
62.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-53.7%
Peak to trough
Max drawdown 5Y
-97.5%
Peak to trough
ATR 14
0.31
7.29% of price
Beta (reported)
1.61
5Y monthly, from filing
Short interest
Shares short
202.75K
Prior 269.35K
Change vs prior
-24.7%
Shorts covering
% of float
2.30%
Normal
% of shares out
1.18%
Against total outstanding
Days to cover
1.9
Liquid
Float
12.41M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 25 | Brookline Capital | UPGRADE | Hold | Buy |
| May 14, 25 | Needham | MAINTAINED | Hold | Hold |
| Apr 9, 25 | Needham | MAINTAINED | Hold | Hold |
| Apr 8, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Mar 12, 25 | Needham | MAINTAINED | Hold | Hold |
| Dec 20, 24 | Needham | MAINTAINED | Hold | Hold |
| Nov 6, 24 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Nov 5, 24 | Needham | MAINTAINED | — | Hold |
| Nov 5, 24 | RBC Capital | DOWNGRADE | Outperform | Sector Perform |
| Oct 21, 24 | TD Cowen | MAINTAINED | Buy | Buy |
| Oct 4, 24 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Oct 3, 24 | Needham | DOWNGRADE | Buy | Hold |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:10
Split dateJul 25, 2025
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-09
Corporate Changes & Voting Matters
8-K · 2026-05-12
Proxy Statements
DEFA14A · 2026-04-20
Periodic Financial Reports
10-K · 2026-03-11
Corporate Changes & Voting Matters
8-K · 2025-12-30
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2025-12-19
Offering Registrations
S-3 · 2025-12-15
Headlines
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
GlobeNewswire · 7d ago
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
GlobeNewswire · 27d ago
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 29d ago
Verrica completes enrolment in Phase III trial of Ycanth
Hospital Management · 40d ago
Lake Street Initiates Verrica Pharmaceuticals at Buy With $9 Price Target
MT Newswires · 40d ago
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
GlobeNewswire · 41d ago
Verrica Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 61d ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.